1. Home
  2. BL vs OGN Comparison

BL vs OGN Comparison

Compare BL & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackLine Inc.

BL

BlackLine Inc.

HOLD

Current Price

$28.44

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Organon & Co.

OGN

Organon & Co.

HOLD

Current Price

$13.39

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BL
OGN
Founded
2001
1923
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
BL
OGN
Price
$28.44
$13.39
Analyst Decision
Buy
Hold
Analyst Count
13
5
Target Price
$56.62
$11.40
AVG Volume (30 Days)
1.5M
3.4M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
0.60%
EPS Growth
N/A
N/A
EPS
0.13
0.55
Revenue
$177,031,000.00
$6,216,000,000.00
Revenue This Year
$12.62
$0.45
Revenue Next Year
$10.90
$1.67
P/E Ratio
$220.85
$24.36
Revenue Growth
43.78
N/A
52 Week Low
$24.70
$5.69
52 Week High
$59.57
$13.48

Technical Indicators

Market Signals
Indicator
BL
OGN
Relative Strength Index (RSI) 45.60 74.42
Support Level $25.49 $10.05
Resistance Level $30.93 $13.46
Average True Range (ATR) 1.96 0.04
MACD 0.21 -0.19
Stochastic Oscillator 41.75 34.62

Price Performance

Historical Comparison
BL
OGN

About BL BlackLine Inc.

BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.

About OGN Organon & Co.

Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.

Share on Social Networks: